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Background. Transmitted human immunodeﬁciency virus type 1 (HIV) drug resistance (TDR) mutations are
transmitted from nonresponding patients (deﬁned as patients with no initial response to treatment and those with
an initial response for whom treatment later failed) or from patients who are naive to treatment. Although the prev-
alence of drug resistance in patients who are not responding to treatment has declined in developed countries, the
prevalence of TDR mutations has not. Mechanisms causing this paradox are poorly explored.
Methods. We included recently infected, treatment-naive patients with genotypic resistance tests performed ≤1
year after infection and before 2013. Potential risk factors for TDR mutations were analyzed using logistic regression.
The association between the prevalence of TDR mutations and population viral load (PVL) among treated patients
during 1997–2011 was estimated with Poisson regression for all TDR mutations and individually for the most frequent
resistance mutations against each drug class (ie, M184V/L90M/K103N).
Results. We included 2421 recently infected, treatment-naive patients and 5399 patients with no response to treat-
ment. The prevalence of TDR mutations ﬂuctuated considerably over time. Two opposing developments could explain
these ﬂuctuations: generally continuous increases in the prevalence of TDRmutations (odds ratio, 1.13; P = .010), punc-
tuated by sharp decreases in the prevalence when new drug classes were introduced. Overall, the prevalence of TDR
mutations increased with decreasing PVL (rate ratio [RR], 0.91 per 1000 decrease in PVL; P = .033). Additionally, we
observed that the transmitted high-ﬁtness-cost mutation M184V was positively associated with the PVL of nonres-
ponding patients carrying M184V (RR, 1.50 per 100 increase in PVL; P < .001). Such association was absent for
K103N (RR, 1.00 per 100 increase in PVL; P = .99) and negative for L90M (RR, 0.75 per 100 increase in PVL; P = .022).
Conclusions. Transmission of antiretroviral drug resistance is temporarily reduced by the introduction of new drug
classes and driven by nonresponding and treatment-naive patients. These ﬁndings suggest a continuous need for new
drugs, early detection/treatment of HIV-1 infection.
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Transmission of human immunodeﬁciency virus type 1 (HIV-
1) infection depends strongly on individual levels of plasma
viremia [1]. When HIV-1–infected patients receive suboptimal
treatment or have incomplete adherence to antiretroviral therapy
(ART), drug-resistant viruses emerge and continue replicating.
Therefore, the general assumption is that drug-resistant viruses
are mainly transmitted from treated patients with high levels of
HIV viremia due to failed treatment [2]. Modern ART reduces
the viremia levels and transmissibility of HIV-1 more effectively
than earlier ART [3], suggesting less emergence [4] and transmis-
sion of drug resistance mutations over time.
In recent years, the incidence and prevalence of acquired
drug resistance (ADR) mutations in treated patients has indeed
declined because of effective ART in various developed coun-
tries [5, 6]. However, the prevalence of transmitted drug resis-
tance (TDR) mutations has often remained stable [7–9]. TDR
mutations may cause early virological failure when patients
start their ﬁrst-line therapy [10]. Certain TDR mutations can
persist for years in the absence of drug pressure after serocon-
version [11] and have long-term potential to jeopardize the ef-
fectiveness of ART; other TDR mutations may disappear
rapidly and become undetectable via population sequencing
[11, 12]. Recently, transmission of minority variants harboring
drug resistance mutations has been demonstrated [13]. Difﬁcul-
ties in detecting TDR mutations upon ART initiation might
therefore compromise the treatment success achieved thus far.
In the current study, we aimed at analyzing the risk factors for
TDRmutations and resolving the discrepant patterns in the prev-
alences of TDR mutations and ADR mutations over time. The
unique data set of the Swiss HIV Cohort Study (SHCS), which
is representative for ≥15 years, allows us to determine the impact
of temporarily changing factors, such as numbers of available
drug classes. We used population viral load (PVL) as a tool to
assess the spread of drug resistance and the transmission potential
of the treatment-experienced population. We focused speciﬁcally
on TDR mutations during recent infections, to avoid potential
bias caused by different times of TDR mutation persistence.
METHODS
Study Population
The SHCS, which has been enrolling patients since 1988, is a pro-
spective, nationwide, clinic-based study that includes a biobank.
The SHCS reﬂects the epidemiologic characteristics of HIV infec-
tion in Switzerland: it includes at least 53% of all cases of HIV
infection ever diagnosed in Switzerland, 72% of all patients receiv-
ing ART, and 69% of the nationwide registered AIDS cases [14].
Additionally, we enrolled patients from the Zurich Primary HIV
Infection study (clinical trials registration NCT00537966), which
focuses on identifying and treating patients during early infection
[15]. Ethical approval from all participating institutions and writ-
ten informed consent from all patients was obtained [14–16].
To identify the prevalence of TDRmutations, we included re-
cently infected, treatment-naive patients, as deﬁned below, with
a genotypic resistance test performed before 1 January 2013.
The ﬁrst genotypic resistance test from each recently infected,
treatment-naive individual was considered. All sequences de-
termined before 1996 were grouped together because of small
sample sizes. For the association analysis, in which we tested
whether the TDR mutation prevalence was associated with
the PVL for nonresponding patients (deﬁned as patients with
no initial response to treatment and those with an initial re-
sponse for whom treatment later failed), we included nonres-
ponding patients enrolled from 1997 to 2011, owing to the
representative availability of viral load testing since 1997.
Genotypic resistance tests were performed as part of routine
clinical testing by 4 laboratories in Switzerland authorized by
the Federal Ofﬁce of Public Health. All laboratories perform
population-based sequencing of the full protease gene and at
least codons 28–225 of the reverse transcriptase gene, using
commercial assays (Viroseq Vs.1, PE Biosystems; Virsoseq Vs.
2, Abbott; and vircoTYPE HIV-1 Assay, Virco Lab) and in-
house methods [17], and have participated in the yearly quality
control evaluation by the Agence Nationale de la Recherche du
SIDA since 2002. All sequences are entered into the SHCS drug
resistance database, using SmartGene’s Integrated Dababase
Network System (SmartGene, Zug, Switzerland; IDNS version
3.6.3) [18]. Additionally, we performed systematic retrospective
sequencing of virus from blood samples that were stored in the
biobank before routine genotyping was introduced (>11 000 se-
quences were retrospectively generated). Subtyping was
performed on the protease and reverse transcriptase sequences,
using REGA 2 (http://jose.med.kuleuven.be/genotypetool/html/
subtypinghiv.html). If this method returned inconclusive re-
sults, the analysis was repeated with the Star analyzer (http://
www.vgb.ucl.ac.uk/starn.shtml) [19].
TDRmutationswere identiﬁed using theWorldHealth Organi-
zation list for surveillance of transmitted HIV drug resistance [20].
Deﬁnition of Recent Infection
To account for potential reversion of TDR mutations in the ab-
sence of drug pressure [11, 21–25], we restricted our study pop-
ulation to treatment-naive patients who received their diagnosis
≤1 year after infection. We determined recent infection on the
basis of satisfaction of at least one of 3 criteria. The ﬁrst criterion
was documented acute HIV-1 infection, as previously described
[15].The second criterion was documented seroconversion (with
<1 year having passed between the last negative result and ﬁrst
positive result of a test to detect HIV). For those lacking the
data mentioned above, the ambiguity score [26] was used as a
third criterion. The ambiguity score is a measure of the viral nu-
cleotide diversity determined using bulk sequencing, which pro-
vides an estimate of the infection duration. Sequences in which
≤0.5% of the nucleotides are ambiguous indicate that the
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genotypic resistance test was performed on a recently infected pa-
tient [26]. However, because diversity may be low in long-term
HIV infections, patients with a score ≤0.5% and a CD4+ T-cell
count of <200 cells/μL were excluded to reduce false positives.
For validation of this method, see the Supplementary Materials.
Viral Burden Among Nonresponders
PVL was used to describe the viral burden of nonresponding pa-
tients for the coming year on a population level. We summed the
log10-transformed viral loads from all nonresponding patients of a
given year. For further analyses, in which we studied the transmis-
sion pattern of a speciﬁc TDRmutation, the total log10-transformed
viral loads fromnonresponding patients carrying the corresponding
mutation was used. Only viral loads corresponding to a genotypic
resistance test were included for these analyses because genotyping
was needed to determine drug resistance mutations.
To acquire all potential treatment failures, we deﬁned treat-
ment failure as having a viral load of ≥400 copies/mL after re-
ceiving ART continuously for 180 days of continuous ART.
Viral load measurement was not fully integrated into the clini-
cal routine before 1997, so we included viral loads from nonres-
ponding patients during 1997–2011. Each person contributed
to each year once. If a patient had ≥2 viral load measurements
within the same year, we calculated the mean for that year.
Statistical Methods
Potential risk factors for acquiring any TDR mutations were ana-
lyzed using logistic regression. Variables investigated were ethnicity
(white, black, or other), sex (male or female), transmission group
(men having sex with men, heterosexuals, injection drug users, or
other), HIV-1 subtype (B or non-B), and calendar year of sampling
(ﬁtted as a continuous variable). Additionally, since we suspected
that less optimal regimens resulting from fewer choices of available
drugs might have inﬂuenced TDR mutation transmission, we in-
cluded the number of available drug classes as an ordered categor-
ical variable (the P value was obtained from the test for trend). In
Switzerland,HIV-1 treatment can be classiﬁed into 5 eras, each sep-
arated by the introduction of a new drug class. Monoclass therapy
with nucleoside analogue reverse transcriptase inhibitors (NRTIs)
was used before 1996 (1 drug class: before 1997).After the introduc-
tion of unboosted protease inhibitors (PIs) in 1996, patients could
obtain dual-class regimens (2 drug classes: 1997–1998). Subse-
quently, nonnucleoside analogue reverse transcriptase inhibitors
(NNRTIs) were introduced in 1998 (3 drug classes: 1999–2000),
followed by ritonavir-boosted PI (PI/r) in 2000 (4 drug classes:
2001–2008) and integrase inhibitor (InSTI) in 2008 (5 drug classes:
2009–2012). In themodel,we included abinary response indicating
detection of any TDR mutation from each patient as an outcome.
We analyzed variables independently and included those (ie, HIV
subtype and transmission group) that were signiﬁcantly associated
with the outcome into themultivariable model.We also chose var-
iables a priori, regardless of univariable signiﬁcance, owing to likely
biological impacts (sex, year, and number of available drug classes).
For TDR mutations to individual drug classes, we included the
same covariables in the multivariable models for reasons of consis-
tency, to avoid obtaining a different set of variables for each drug
class. We found no collinearity and interactions between any
included variable. Missing data were list-wise deleted. We calcu-
lated the odds of TDR mutation detection from our ﬁtted mul-
tivariable model by retaining all covariables except year and
number of available drug classes at baseline and transformed
the predicted odds to annual prevalences.
In the association analysis, we used Poisson regression to as-
sess the association of TDRmutation transmission with nonres-
ponding patients as potential transmitters. We considered
annual rates of genotypic resistance tests detecting TDR muta-
tions from recently infected, treatment-naive patients as the
outcome and PVL of all nonresponding patients from the pre-
vious year as the explanatory variable. We further studied the
association for the most prevalent drug resistance mutation
for each major drug class in the SHCS: M184V, L90M, and
K103N for NRTIs, PIs, and NNRTIs, respectively. In this indi-
vidual-mutation analysis, we ﬁtted the model with the annual
prevalence of each of these 3 transmitted mutations as outcome
and the PVL of nonresponding patients carrying the corre-
sponding mutation from the previous year as explanatory vari-
able. We performed sensitivity analyses that included PVLs
measured during the same year as or 2 years before performance
of genotypic resistance tests (Supplementary Materials).
We expressed our results with 95% conﬁdence intervals (CIs)
and 2-sided P values, with a P value of < .05 being statistically
signiﬁcant. Data analyses were performed with Stata 13.0 SE
(StataCorp, College Station, Texas).
Subgroup Analysis
Considering that transmission to some SHCS patients may have
occurred abroad and that the TDR mutation prevalence among
those patients would be less relevant to that among treatment-
experienced patients in Switzerland, we repeated the association
analyses with only those patients found in Swiss transmission
clusters, deﬁned phylogenetically [27]. To summarize, HIV-1
subtype B pol sequences from 8271 SHCS patients were pooled
with foreign pol sequences from the Los Alamos Sequence data-
base (n = 36 230). Clusters were deﬁned as clades containing ≥10
sequences and consisting of ≥80% sequences from the SHCS.
RESULTS
Fraction of Genotypic Resistance Tests With Positive Results
in the SHCS
Figure 1 summarizes the fraction of TDR and ADR mutations
from all 20 120 genotypic resistance tests sampled before 1 Jan-
uary 2013, regardless of the infection duration, stratiﬁed by
treatment status (naive or experienced). Speciﬁcally, 10 504
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genotypic resistance tests were from 7920 treatment-naive indi-
viduals, and 9616 genotypic resistance tests were from 4816
treatment-experienced individuals.
The prevalence of ADR mutations reached a peak of 85% in
1998 and dropped continuously thereafter, reaching a plateau of
approximately 38% in 2009. This strong decrease in the fraction of
genotypic resistance tests positive for ADR mutations (linear re-
gression,−2.8% [95% CI,−3.4% to−2.2%] per year; P < .001) was
followed not by a parallel decrease but, rather, by a slight increase
in the fraction of genotypic resistance tests positive for TDR mu-
tations (0.3% [95% CI, .2%–.5%] per year; P < .001). To further
dissect this discrepancy and to avoid possible bias introduced
by different persistence times for TDR mutations, we focused
on studying treatment-naive patients with genotypic resistance
tests performed recently after infection acquisition.
Study Population
We identiﬁed 2421 recently infected patients (31%) from 7920
treatment-naive patients in the SHCS with ≥1 genotypic resis-
tance test performed between 26 June 1992 and 18 December
2012. Additionally, we included 5399 who were nonresponders
to ≥1 regimen during 1997–2011, presenting 18 097 yearly uni-
que viral load measurements. For detailed patient-selection
methods, see Figure 2. For details on the representativeness of
the study population, see Supplementary Figure 1.
TDR Mutation Prevalence Over Time in Recently Infected
Treatment-Naive Patients and Associated Risk Factors
Median TDRmutation prevalences ﬂuctuated substantially over
time, as follows: 9.1% (range, 2.2%–15.6%) to any drug, 5.8%
(range, 2.2%–14.3%) to an NRTI, 2.5% (range, 0%–4.8%) to a
PI, and 1.4% (range, 0%–5.1%) to an NNRTI (Figure 3).
We observed 2 opposing developments in the multivariable lo-
gistic model that could explain the complex ﬂuctuations of TDR
mutation prevalences (Table 1). On one hand, the overall TDR
mutation prevalence dropped after introduction of new drug clas-
ses. In particular, prevalences signiﬁcantly dropped after PI/r and
InSTI became available. On the other hand, we found a linear in-
crease of TDRmutation prevalences when the number of available
drug classes remained constant (Figure 3). The combination of
Figure 1. Fraction of positive genotypic resistance tests detecting any drug resistance mutation for acquired and transmitted drug resistance in the Swiss
HIV Cohort Study (SHCS). A total of 20 120 genotypic resistance tests were performed before 1 January 2013 in the SHCS. A total of 10 504 genotypic
resistance tests (blue triangles) were performed for 7920 patients when they were treatment naive (regardless of recent infection), and 9616 genotypic
resistance tests (red dots) were performed for 4816 individuals when they were treatment experienced. Fractions of genotypic resistance tests positive for
any drug resistance mutation for both populations are shown. The annual numbers of included genotypic resistance tests from treatment-experienced (ﬁrst
row; red) and treatment-naive (second row; blue) patients are listed below the graph. Linear regression analysis with fraction as the dependent variable and
year as the explanatory variable showed that the fraction of drug resistance tests with positive results among treatment-experienced patients has declined
substantially over time (−2.8% [95% conﬁdence interval {CI}, −3.4% to −2.2%] per year; P < .001), whereas the fraction among treatment-naive patients
has not (0.3% [95% CI, .2%–.5%] per year; P < .001). Vertical bars denote 95% CIs.
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these 2 opposing developments resulted in TDR mutation preva-
lences, which increased in the absence of new drugs but decreased
sharply upon introduction of new drug classes. TDR mutation
prevalences predicted from this model are shown in Figure 3.
Additionally, prevalences of TDR mutations for indivi-
dual drug classes showed similar but not statistically signiﬁcant
patterns, as mentioned above (Supplementary Table 1.1–1.3).
Association of TDR Mutation Transmission With Viral Burden in
Nonresponding Patients
We further investigated whether TDRmutation transmission was
associated with nonresponse to treatment. We ﬁtted annual prev-
alences of any TDR mutation (outcome) and the PVL of nonres-
ponding patients from the previous year (explanatory variable)
with a Poisson regression model. The rate ratio (RR) was 0.91
Figure 2. Patient selection proﬁle. Numbers outside of the boxes indicate exclusions. A, Selection proﬁle for the recently infected, treatment-naive
population. We selected patients enrolled in the Swiss HIV Cohort Study (SHCS) before 1 January 2013 with genotypic resistance tests (GRTs) performed
when they were treatment naive (n = 7920). Of these, we identiﬁed patients with GRTs performed during recent infection (≤1 year of infection) according to
documented infection dates, seroconversions, or ambiguity score and CD4+ T-cell count. These patients constitute our basic study population (n = 2421). For
further analyses, such as for the univariable and multivariable analysis in Table 1, and for the association analyses in Figure 4A–4D, 66 and 252 patients,
respectively, were excluded because of additional criteria set for these analyses. Sixty-six patients did not have a clearly deﬁned subtype, and 252 patients
were not sampled during 1998–2012 (for details, see individual descriptions in Table 1 and Figure 4). B, Selection proﬁle for the nonresponding population.
We chose population viral load (PVL) as an indicator for the viral burden for nonresponding patients on a population level. PVL was deﬁned as the sum of
log10-transformed viral loads from nonresponding patients. We thus selected available viral load measurements from SHCS patients when they were treat-
ment experienced. High viral loads (≥400 copies/mL) measured after 180 days of and during continuous therapy were included from these patients. Because
viral load testing has been fully integrated into routine clinical care since 1997, values before 1997 were excluded. We calculated a yearly unique viral load
from each patient (if ≥1 viral load was available per patient within the same year, the mean was used) and used these values for the association analysis
reported in Figure 4E. For further association analyses, shown in Figure 4F–4H, in which we studied the transmission pattern of a speciﬁc transmitted drug
resistance mutation, only viral loads corresponding to a GRT were included because genotyping was needed to determine drug resistance mutations. From
viral loads with corresponding GRTs, we selected those from patients carrying M184V, L90M, or K103N for association analysis in Figure 4F, 4G, or 4H,
respectively. Abbreviations: HIV-1, human immunodeﬁciency virus type 1; ZPHI, Zurich Primary HIV Infection study.
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(95% CI, .83–.99) per 1000 increase in PVL [of sum of log10
transformed viral load] (P = .033), indicating a 9% increase
in the TDR mutation prevalence per 1000 decrease in the
PVL from the previous year of non-failing patients (Figure 4A
and 4E ). The PVL itself decreased over time (linear regression,
−318 [95% CI, −438 to −197] per year; P < .001). When we
considered patients identiﬁed in Swiss transmission clusters,
we found no discernible evidence for an association between
TDR mutations and PVL (RR, 0.76 [95% CI, .43–1.34] per
1000; P = .34).
Figure 3. Observed and predicted transmitted drug resistance (TDR) mutation prevalences. A total of 2421 recently infected, treatment-naive patients
with their ﬁrst genotypic resistance tests were included. For each year, we calculated the percentage of genotypic resistance tests detecting TDR mutations
(black dots) to any drug (A), nucleoside reverse transcriptase inhibitors (NRTIs; B), protease inhibitors (PIs; C), and nonnucleoside reverse transcriptase
inhibitors (NNRTIs; D). Additionally, we predicted the TDR mutation prevalence (blue dashed lines) by holding all covariables except year and number
of available drug classes at baseline from the multivariable logistic regression model (Table 1) and transforming the odds obtained from the model. Co-
variables included in the model were human immunodeﬁciency virus type 1 (HIV-1) subtype and transmission group, owing to univariable signiﬁcance, and
sex, number of available drug classes, and calendar year, which were chosen a priori. Missing data were list-wise deleted. Total numbers of genotypic
resistance tests included for each year are listed at the bottom of Figure 3 (observed data are black; predicted data are blue). The reason for a smaller sample
size (n = 2355) for the predicted prevalences was that 66 patients were excluded from the multivariable model because of nonclassiﬁed HIV-1 subtypes. We
found that the large ﬂuctuations of the observed TDR mutation prevalences (black dots) could be explained by 2 opposing developments: (1) a continuous
increase in prevalence with time when no new drug classes were introduced, and (2) a sharp decrease in prevalence when a new drug class was introduced
(orange vertical lines). This combined effect was described by the predicted TDR mutation prevalence (blue dashed lines). Vertical bars denote 95%
conﬁdence intervals.
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Together, our results suggested no or a negative association
between TDR mutation prevalences and PVL of nonresponding
patients from the previous year.
Transmission of the Class-Speciﬁc Drug-Resistance Mutations
M184V, L90M, and K103N
The above analysis pooled all TDR mutations and potential-
ly neglected the differential behavior of individual muta-
tions. We therefore performed individual-mutation analysis
for the most prevalent drug resistance mutation for each drug
class.
The prevalence of transmitted M184V increased 1.5-fold
per 100 increase in the PVL from the previous year among
nonresponding patients carrying M184V (RR, 1.50 [95% CI,
1.20–1.86] per 100 increase in the PVL; P < .001; Figure 4B
and 4F ). This association increased to approximately 6-fold
when only TDR mutations from Swiss transmission clusters
were considered (RR, 5.68 [95% CI, 1.21–26.7] per 100 in-
crease in the PVL; P = .028). On the contrary, we observed a
negative association between the prevalence of transmitted
L90M and the PVL in nonresponding patients carrying
L90M during the previous year (RR, 0.75 [95% CI, .58–.96]
per 100 increase in the PVL; P = .022; Figure 4C and 4G); the
association became stronger when TDR mutations from Swiss
transmission clusters were considered (RR, 0.07 [95% CI,
.01–.46] per 100 increase in the PVL; P = .006). For K103N,
no association was detected (RR, 1.00 [95% CI, .73–1.37] per
100 increase in the PVL; P = .99; Figure 4D and 4H), and the
RR became negative when the analysis included only patients
from Swiss transmission clusters but did not reach statistical
Table 1. Univariable and Multivariable Analysis for the Overall Transmitted Drug Resistance (TDR) Mutation Prevalences
Factor Valuea
OR (95% CI) in
Univariable Analysis P values
OR (95% CI) in
Multivariable Analysis P values
Age 35 (28–42) 1.00 (.98–1.01) .62 . . .
Ethnicity .33
White 182/1985 (9.2) 1.00 (Reference) . . .
Black 16/222 (7.2) 0.77 (.45–1.31) . . .
Otherb 9/148 (6.1) 0.64 (.32–1.28) . . .
HIV subtype <.01 .03
B 167/1683 (9.9) 1.00 (Reference) 1.00 (Reference)
Non-B 40/672 (6.0) 0.57 (.40–.82) 0.65 (.43–.98)
Sex .07 .10
Male 173/1853 (9.3) 1.00 (Reference) 1.00 (Reference)
Female 34/502 (6.8) 0.71 (.48–1.03) 0.96 (.60–1.55)
Transmission group .03 .62
MSM 129/1248 (10.3) 1.00 (Reference) 1.00 (Reference)
Heterosexuals 52/770 (6.8) 0.63 (.45–.88) 0.83 (.52–1.30)
Injection drug users 22/263 (8.4) 0.79 (.49–1.27) 0.86 (.51–1.45)
Others 4/74 (5.4) 0.50 (.18–1.38) 0.57 (.20–1.60)
No. of available drug classes (type[s]) .77 .06c
1 (NRTI) 10/125 (8.0) 0.97 (.49–1.91) 2.99 (.99–9.02)
2 (NRTI, PI) 20/220 (9.1) 1.12 (.68–1.84) 2.85 (1.19–6.83)
3 (NRTI, PI, NNRTI) 25/235 (10.6) 1.33 (.84–2.11) 2.75 (1.36–5.55)
4 (NRTI, PI, NNRTI, PI/r) 103/1252 (8.2) 1.00 (Reference) 1.00 (Reference)
5 (NRTI, PI, NNRTI, PI/r, InSTI) 49/523 (9.4) 1.15 (.81–1.65) 0.61 (.34–1.07)
Year 2005 (2001–2008) 1.02 (.98–1.05) .32 1.13 (1.03–1.23)d .01
Data are no. with resistance/total no. in subgroup (%) or median value (range). We used logistic regression to model the odds of being detected as carrying TDR
mutation. The dependent variable was included as a binary response indicating whether any TDR was detected. All covariables were categorical, except for age and
year, which were continuous variables. In the multivariable model, we included significant variables from a univariable model (ie, human immunodeficiency virus
subtype and transmission group). Variables chosen a priori to be included regardless of univariable significance were sex, no. of available drug classes, and calendar
year. Missing data were list-wise deleted, resulting in the exclusion of 66 patients (2.7% of 2421) because of missing subtype.
Abbreviations: CI, confidence interval; InSTI, integrase inhibitor; MSM, men having sex with men; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI,
nonnucleotide reverse transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor.
a No. of patients with any drug resistance from the 2355 recently infected, treatment-naive patients with a clearly defined subtype.
b Includes Asian, Hispanic, other, and unknown.
c Obtained from the test for trend.
d Increment is per year.
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signiﬁcance (RR, 0.02 [95% CI, .0002–1.55] per 100 increase in
the PVL; P = .078).
Sensitivity analyses using PVL from different years and valida-
tion of the ambiguity score for identifying recent infections
showed that our results were robust (Supplementary Tables 2,
3.1, and 3.2). For a summary of the sample sizes and methods
used in each analysis, see Supplementary Table 4.
DISCUSSION
In this study, we investigated the paradox between the decrease in
ADR mutation prevalence [5, 6, 28] and a nearly stable preva-
lence of TDR mutations [7, 8, 29–31]. If TDR mutations indeed
primarily originate from nonresponding patients with ADR
mutations, this discrepancy is counterintuitive. We therefore
tested whether transmission of drug-resistant viruses was
dependent on nonresponding patients in the SHCS, which is
representative of the HIV-infected population in Switzerland,
over a 15-year period. A large, treatment-naive population
with clearly deﬁned recent infection was used to calculate the
TDR mutation prevalences.
Our results indicate that drug resistance transmission is pre-
dominantly driven not by nonresponding patients but, rather,
by a complex mixture of both nonresponding and ART-naive
patients. Although the PVL of nonresponding patients decreased
continuously, TDR mutation prevalences increased over time.
When speciﬁc TDR mutations were studied individually, distinct
transmission patterns emerged. The prevalence of transmitted
Figure 4. Association analysis for transmitted drug resistance (TDR) mutation prevalences with the population viral load (PVL) for nonresponding patients
from the previous year. Poisson regression was used to test the association between TDR mutations and the PVL for nonresponding patients from the
previous year. A total of 2169 recently infected, treatment-naive patients with genotypic resistance tests performed during 1998–2012 were included
as the outcome to account for annual prevalences of any TDR mutation (A), transmitted M184V (B), transmitted L90M (C), and transmitted K103N (D).
Included as an explanatory variable was the PVL of all nonresponding patients (E ) and the PVL of nonresponding patients carrying M184V (F ), L90M
(G), and K103N (H) during 1997–2011. Total numbers of genotypic resistance tests performed for recently infected, treatment-naive patients for each
year are listed in the ﬁrst row of the table at the bottom of the ﬁgure. Annual numbers of yearly unique viral loads for all nonresponding patients,
noted as PVL (all nonresponding patients), and PVL (nonresponding patients with a speciﬁc mutation) are listed in rows 2–4. We found that the PVL of
all nonresponding patients decreased over time (E; linear regression: −318 [95% conﬁdence interval {CI}, −438 to −197] per year; P < .001). The annual
prevalence of any TDR mutation was negatively associated with the PVL of nonresponding patients from the previous year (A and E; rate ratio [RR], 0.91
[95% CI, .83–.99] for every 1000 decrease in PVL; P = .033). The prevalence of transmitted M184V was positively associated with the PVL from
nonresponding patients carrying M184V from the previous year (B and F; RR, 1.50 [95% CI, 1.20–1.86] for every 100 increase in PVL; P < .001). On the
other hand, a negative association was found for L90M (C and G; RR, 0.75 [95% CI, .58–.96] per 100 increase in PVL; P = .022), and no association was found
for K103N (D and H; RR, 1.00 [95% CI, .73–1.37] per 100 increase in PVL; P = .99).
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M184V correlated positively with PVL from nonresponding
patients carrying M184V from the previous year. This as-
sociation became stronger for patients included in Swiss trans-
mission clusters. This suggests that the nonresponding
population is the major transmission source for M184V. In
contrast, no positive association was found for L90M or
K103N. We detected a negative association between prevalences
of transmitted L90M and the PVL among nonresponding
patients carrying L90M from the previous year. This implies
that major transmission reservoirs for these mutations are
treatment-naive rather than nonresponding patients.
How can we explain such divergent transmission patterns be-
tween speciﬁc drug resistance mutations? It is most likely due to
the differential ﬁtness costs, which represent the reduced ability
of a virus harboring a drug resistance mutation to replicate in the
absence of the drug to which the mutation confers resistance.
Generally, drug-resistant viruses will be replaced gradually by ﬁt-
ter viruses when drug pressure is not present, and the rate of the
replacement depends on the degree of the ﬁtness cost [32].
M184V disappears at a fast rate after transmission [11] without
drug pressure, owing to its high ﬁtness cost [33]. Therefore,
M184V was rarely found in a drug-naive population, and its
transmission depends on nonresponding patients. In contrast,
the low-ﬁtness-cost mutations L90M and K103N [23, 34, 35] per-
sist longer in the absence of drug pressure [23] and may therefore
persist within the ART-naive population, which thus becomes an
important source for transmission of these mutations.
This interpretation is further supported by the fact that oc-
currence of L90M among recently infected, treatment-naive pa-
tients has increased years after the PVL from nonresponding
patients carrying L90M started to decrease (Figure 4), resulting
in the negative association yielded by the Poisson regression. A
similar but weaker phenomenon was observed for K103N. Var-
ious combinatorial ART regimens might contribute to differ-
ences between transmission patterns of L90M and K103N.
Drugs selecting for L90M, mainly saquinavir and nelﬁnavir,
have been almost unused in Switzerland for many years, indi-
cating circulation of transmitted L90M within the treatment-
naive population. On the other hand, drugs selecting for
K103N, such as efavirenz and nevirapine, are still in heavy
use, implying that transmission of K103N is fueled both by
nonresponding and treatment-naive patients.
Complemented by results from previous phylogenetic analy-
ses [36–38], our study further illustrates that the treatment-
naive population is a major source for ongoing transmission
of low-ﬁtness-cost mutations. Early diagnosis and treatment
of HIV-1 infection is warranted to block the otherwise self-
fueling mechanism of unrecognized TDR mutations, which
persist in this population because of low ﬁtness costs.
In the SHCS, TDR mutation prevalences ﬂuctuated consider-
ably over time. We hypothesized that introductions of new
drugs had an effect on these ﬂuctuations, because new drugs
improve control of viremia in treated patients. Indeed, after
each introduction of a new drug class, a drop in TDR mutation
prevalence was observed: in 1997 after introduction of PI, 1999
after introduction of NNRTI; in 2001, after introduction of PI/r;
and in 2009, after introduction of InSTI (Figure 3). Despite the
universal and unlimited access to ART in Switzerland, TDR
mutation prevalences could not be reduced over an 18-year
study period (Figure 3A). Possibly, even more TDR mutations
would have occurred without a constant inﬂux of new therapy
options. This highlights the importance of a drug pipeline that
constantly delivers new medications.
There are several limitations to this study. Although our
study was limited to a single country, we believe that our ﬁnd-
ings are generalizable to settings with similar HIV epidemics
and treatment policies (for the generalizability of our ﬁndings,
see the Supplementary Material). In the correlation analyses, we
used measures for nonresponding patients from the previous
year because we assumed that nonresponding patients could
transmit drug resistance approximately within 1 year before sal-
vage treatment is fully active. Sensitivity analyses using the PVL
from the same year or 2 years before revealed results similar to
those of the original model (Supplementary Table 2). Further-
more, the lack of positive associations from individual-mutation
analyses of L90M/K103N does not causally prove that
treatment-naive individuals are the main source for the trans-
mission. Although unlikely because of the well-studied trans-
mission dynamics within the SHCS [27], we cannot exclude
the possibility that patients carrying the transmitted L90M/
K103N in our study population might all have been infected
abroad and thus that the nonresponder PVL as measured in
the SHCS would not be relevant. However, the subgroup anal-
ysis including only patients from Swiss transmission clusters
conﬁrmed the same ﬁnding.
In summary, we demonstrated that transmission of antiretro-
viral drug resistance is temporarily reduced by the introduction
of new drug classes and driven both by nonresponding and
treatment-naive patients. These ﬁndings suggest a continuous
need for new drugs and for early detection and treatment of
HIV-1 infection to successfully control the spread of TDR mu-
tations in the long term.
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